Introduction
Ovarian cancer is a considerable therapeutic challenge for clinicians and outcomes for the disease have not changed dramatically for several decades. This year, more than 20,000 women in the United States will be diagnosed with ovarian cancer, and nearly 15,000 will succumb to the disease. The 16th International Meeting of the European Society of Gynaecological Oncology (ESGO), held in Belgrade, Serbia provided an excellent forum to discuss, debate, and disseminate much needed new clinical and scientific information. Highlights from novel ovarian cancer presentations are outlined in this newsletter.
Editors
Robert L. Coleman, MD, FACOG, FACS, bio | Beth Y. Karlan, MD, FACOG, FACS, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: November 13, 2009 | Expiration date: November 12, 2010
Statement of Need
New therapies, new combinations of existing chemotherapies, and new methods of delivery of local and systemic therapies have been shown to improve survival for patients with ovarian cancer. While improvements are being realized, many issues surrounding the management of ovarian cancer remain. Included are the utility of CA125 within clinical trials as a means of assessing clinically significant progression, choice of agent(s), use of monotherapy versus combination regimens, and the timing of salvage therapy. This educational program will provide medical oncologists, gynecologic oncologists, and healthcare professionals caring for patients with ovarian cancer with pertinent information about advances in the management of ovarian cancer.
Target Audience
The target audience for the program will include gynecologic oncologists, medical oncologists, surgical oncologists, pathologists, and allied healthcare professionals caring for patients with ovarian cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Recognize biologic pathways of significance in ovarian cancer pathogenesis and resistance
- Examine current treatment options in the management of ovarian cancer
- Propose an appropriate regimen for patients with either newly diagnosed or recurrent ovarian cancer
- Discuss toxicity prevention, identification, and management strategies for patients receiving therapy for ovarian cancer
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
|
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 199-000-09-078-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity.
During the period November 13, 2009 through November 12, 2010, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE
Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech BioOncology. |
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Robert L. Coleman, MD, FACOG, FACS
Consultant Fees
Abbott Laboratories, Eli Lilly and Company, GlaxoSmithKline, Morphotek, Inc., Ortho Biotech Inc., Pfizer Inc
Honorarium
Eli Lilly and Company, GlaxoSmithKline, Morphotek, Inc., Ortho Biotech Inc.
Speakers’ Bureau
Eli Lilly and Company, GlaxoSmithKline, Ortho Biotech Inc.
Beth Y. Karlan, MD, FACOG, FACS
No relationships to disclose
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
ACKNOWLEDGEMENT
The faculty wish to thank Sara Fagerlie, PhD, a paid employee of ECG, for assistance in writing this document.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
